Drug Profile
Ocular inflammation therapeutic - Tibet Rhodiola Pharmaceutical
Alternative Names: IL-1-Ra; Recombinant human interleukin-1 receptor antagonist protein - Tibet Rhodiola PharmaceuticalLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Tibet Rhodiola Pharmaceutical Holding Co Ltd
- Class Eye disorder therapies; Recombinant proteins
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ocular inflammation
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for phase-I development in Ocular-inflammation in China (Ophthalmic, Drops)
- 04 Jan 2018 Phase-I clinical trials in Ocular inflammation in China (Ophthalmic)
- 18 Dec 2017 Chengdu Rhodiola Bio-Pharmaceutical initiates enrolment in a phase I trial in Healthy volunteers in China (NCT03383276)